JP2014224134A5 - - Google Patents

Download PDF

Info

Publication number
JP2014224134A5
JP2014224134A5 JP2014154804A JP2014154804A JP2014224134A5 JP 2014224134 A5 JP2014224134 A5 JP 2014224134A5 JP 2014154804 A JP2014154804 A JP 2014154804A JP 2014154804 A JP2014154804 A JP 2014154804A JP 2014224134 A5 JP2014224134 A5 JP 2014224134A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
isolated peptide
acid sequence
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014154804A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014224134A (ja
JP6019457B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014224134A publication Critical patent/JP2014224134A/ja
Publication of JP2014224134A5 publication Critical patent/JP2014224134A5/ja
Application granted granted Critical
Publication of JP6019457B2 publication Critical patent/JP6019457B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014154804A 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法 Active JP6019457B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87362706P 2006-12-08 2006-12-08
US60/873,627 2006-12-08
US93003407P 2007-05-11 2007-05-11
US60/930,034 2007-05-11

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009540318A Division JP2010512324A (ja) 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Publications (3)

Publication Number Publication Date
JP2014224134A JP2014224134A (ja) 2014-12-04
JP2014224134A5 true JP2014224134A5 (https=) 2016-03-24
JP6019457B2 JP6019457B2 (ja) 2016-11-02

Family

ID=39512272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009540318A Pending JP2010512324A (ja) 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法
JP2014154804A Active JP6019457B2 (ja) 2006-12-08 2014-07-30 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2009540318A Pending JP2010512324A (ja) 2006-12-08 2007-12-07 ウロキナーゼ型プラスミノーゲン活性化因子受容体エピトープ、それに由来するモノクローナル抗体及びそれらの使用方法

Country Status (9)

Country Link
US (1) US8105602B2 (https=)
EP (1) EP2117571B1 (https=)
JP (2) JP2010512324A (https=)
CA (1) CA2671971C (https=)
DK (1) DK2117571T3 (https=)
ES (1) ES2636451T3 (https=)
PL (1) PL2117571T3 (https=)
PT (1) PT2117571T (https=)
WO (1) WO2008073312A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1765397E (pt) * 2004-05-25 2013-02-04 Tactic Pharma Llc Anticorpos inibidores que se ligam ao complexo ativador plasminogénico do tipo uroquinasa (upa) e seu receptor (upar)
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
WO2009126725A1 (en) * 2008-04-09 2009-10-15 The Regents Of The University Of Michigan Method of modulating neovascularization
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
AU2010329904B2 (en) * 2009-12-09 2015-07-09 Bayer Pharma Aktiengesellschaft Anti-C4.4a antibodies and uses thereof
US9029509B2 (en) * 2010-02-12 2015-05-12 The Regents Of The University Of California Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR)
AU2011347327A1 (en) 2010-12-22 2013-07-18 Ifom Fondazione Istituto Firc Di Oncologia Molecolare uPAR-antagonists and uses thereof
JP2014529581A (ja) 2011-08-05 2014-11-13 イフォム・フォンダツィオーネ・インスティトゥオ・フィルチ・ディ・オンコロジア・モレコラーレ 構成的に活性なuPARバリアントならびに阻害抗体の生成および単離へのそれの使用
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
WO2015004148A1 (en) 2013-07-08 2015-01-15 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
CA2919687A1 (en) * 2013-08-01 2015-02-05 The General Hospital Corporation Non-glycosylated supar biomarkers and uses thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3350600A4 (en) 2015-09-18 2019-04-17 Baylor College of Medicine DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP7140362B2 (ja) * 2018-04-09 2022-09-21 国立大学法人東海国立大学機構 活性型組換えアクロシン
AU2021292488A1 (en) * 2020-06-15 2023-02-02 Monopar Therapeutics, Inc. Precision radioimmunotherapeutic targeting of the urokinase plasminogen activator receptor (uPAR) for treatment of severe COVID-19 disease
AU2022276433A1 (en) * 2021-05-21 2023-12-07 Monopar Therapeutics Inc. Trivalent radioisotope bio-targeted radiopharmaceutical, methods of preparation and use
CN116410312A (zh) * 2021-12-29 2023-07-11 博生吉医药科技(苏州)有限公司 一种新型upar单域抗体的开发
EP4490511A2 (en) * 2022-03-07 2025-01-15 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN117264061B (zh) * 2023-11-22 2024-03-01 中山大学附属第八医院(深圳福田) 一种识别uPAR的纳米抗体及其应用
WO2025207781A1 (en) 2024-03-26 2025-10-02 Monopar Therapeutics Inc. Antibody radioisotope constructs
WO2025259719A1 (en) * 2024-06-10 2025-12-18 Walden Biosciences, Inc. Method of administering an anti-soluble urokinase plasominogen activator receptor antibody for the treatment of kidney disease
WO2026019458A1 (en) 2024-07-19 2026-01-22 Monopar Therpeutics, Inc Squaramide bi-functional chelators and associated radiopharmaceuticals and methods of use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8721023D0 (en) 1987-09-07 1987-10-14 Lepetit Spa Modified plasminogen activators
IT1228881B (it) 1988-08-12 1991-07-09 Lepetit Spa Anticorpo monoclonale specifico per l'epitopo dell'urochinasi prourichinasi corrispondente alla regione denominata gfd
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
DE69033653T2 (de) * 1989-04-07 2001-06-07 Cancerforskningsfonden Af 1989 (Fonden Til Fremme Af Eksperimental Cancerforskning), Kopenhagen Plasminogen-aktivator-rezeptor vom urokinasetyp
US5519120A (en) * 1989-04-07 1996-05-21 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor antibodies
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
CA2094276C (en) 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
US5561220A (en) * 1991-02-08 1996-10-01 Diatech, Inc. Technetium-99m labeled peptides for imaging inflammation
EP0642354A4 (en) 1991-11-18 1995-07-12 Univ Michigan METHOD FOR DETECTING AND INSULATING uPA-R AND INHIBITING THE BOND uPA WITH uPA-R.
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
ATE190501T1 (de) 1992-05-28 2000-04-15 Univ Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5608110A (en) * 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
US5532132A (en) * 1993-09-28 1996-07-02 President And Fellows Of Harvard University Method for regulating formation of a complex of plasminogen activator, its receptor and inhibitor
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) uPARのドメイン2+3のuPA結合部位および抗体
US5618513A (en) * 1995-06-07 1997-04-08 Mallinckrodt Medical, Inc. Method for preparing radiolabeled peptides
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
ES2274781T3 (es) 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
DE60219888T2 (de) 2001-01-25 2008-01-17 Fondazione Centro San Raffaele Del Monte Tabor Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
US6846484B2 (en) 2001-12-28 2005-01-25 Regents Of The University Of Minnesota DTAT fusion toxin
US20060084056A1 (en) 2002-02-13 2006-04-20 Nadia Harbeck Methods for selecting treatment regimens and predicting outcomes in cancer patients
AU2003216512A1 (en) * 2002-03-18 2003-10-08 Dyax Corporation Integrin ligand
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
WO2004099780A1 (en) 2003-05-06 2004-11-18 Rigshospitalet Immunoassays for the detection of urokinase receptor forms
US20050232924A1 (en) * 2003-11-18 2005-10-20 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US7541159B2 (en) * 2004-04-14 2009-06-02 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Molecular-specific urokinase antibodies
PT1765397E (pt) * 2004-05-25 2013-02-04 Tactic Pharma Llc Anticorpos inibidores que se ligam ao complexo ativador plasminogénico do tipo uroquinasa (upa) e seu receptor (upar)
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
PL2117571T3 (pl) 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy

Similar Documents

Publication Publication Date Title
JP2014224134A5 (https=)
JP2010512324A5 (https=)
JP2017113028A5 (https=)
AR127371A2 (es) Receptores quiméricos de flt3 y métodos para usarlos
NZ581418A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
JP2016526909A5 (https=)
HRP20220080T1 (hr) Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin
JP2016185981A5 (https=)
NZ781142A (en) Anti-vegf protein compositions and methods for producing the same
JP2014518883A5 (https=)
JP2020524510A5 (https=)
RU2014108208A (ru) Мыши с гуманизированной универсальной легкой цепью
JP2015514423A5 (https=)
JP2005120106A5 (https=)
JP2015038108A5 (https=)
JP2015212284A5 (https=)
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
JP2016525100A5 (https=)
WO2016168755A8 (en) Method for mass humanization of non-human antibodies
JP2016512551A5 (https=)
SG10201811172PA (en) A peptide mixture
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2017005987A (es) Anticuerpos anti-interleucina(il)-1beta y metodos de uso.
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
JP2016508503A5 (https=)